The risk for death in patients undergoing anticoagulation therapy for venous thromboembolism was found to be lower in those who were morbidly obese vs those who had normal weight.
Women initiating non-steroidal anti-inflammatory drugs were found to be at increased and comparable risks for venous thromboembolism compared with women not taking these drugs and taking acetaminophen, respectively.
Aspirin was not found to be superior to other anticoagulants in preventing venous thromboembolism after total hip or knee replacement.
Systemic anticoagulation was found to improve quality-adjusted life years among patients with idiopathic pulmonary arterial hypertension but not among those with connective tissue disease-associated pulmonary arterial hypertension.
For patients with DVT, the presence of any component of metabolic syndrome is independently associated with an increased risk for VTE recurrence.
Non-vitamin K antagonist oral anticoagulants may be associated with lower risks for adverse events requiring hospitalization and reduced rates of major bleeding compared with vitamin K antagonists in patients receiving PCI for non-valvular atrial fibrillation who have an indication for anticoagulation.
Researchers examined the association of blood levels of hydroxychloroquine with thrombotic events in a longitudinal systemic lupus erythematous cohort.
Findings show the need for studies addressing the role of anticoagulation therapy in postoperative atrial fibrillation after left-sided heart valve surgery.
The open label, randomized, multicenter, phase 2b/3 DIVERSITY trial evaluated the efficacy and safety of dabigatran compared with SOC (low molecular weight heparin or vitamin K antagonist) in 240 children.
Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.